Novavax undervalued at $716M EV with strong Matrix-M pipeline and key partnerships driving future growth.

Novavax is currently valued at an enterprise value of about $716 million, significantly lower than its peak valuation during the COVID-19 pandemic. Its core value lies in the Matrix-M adjuvant, which has been validated through major partnerships with Sanofi and Pfizer, offering potential milestone payments and royalties. While revenue from product sales like Nuvaxovid has declined sharply, licensing and royalties now drive most of the income. Despite being unprofitable and having an early-stage pipeline, Novavax trades at lower multiples than its biotech peers, making it an attractive investment with upcoming milestone catalysts.